Kezar Life Sciences, Inc. — Director's Dealing 2019

Aug 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2019-08-13

Reporting Person: Fowler John Franklin (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-13	Common Stock	P	2000	$4.655	Acquired	295954	Indirect

Footnotes

F1: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.65 to $4.66 on August 13, 2019. The reporting person will provide upon request to the SEC, the issuer or security holder of issuer, full information regarding the number of shares purchased at each separate price.